Roy Blackburn A.C.I.I. - Senior Account Executive / Client Relationship Representative - Finch, Insurance Brokers | LinkedIn
![Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Oncology Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/07ca0900-4f58-4d67-a25b-02dab75e88cc/gr1.jpg)
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet Oncology
![The hypothalamus-pituitary-adrenal axis in sepsis- and hyperinflammation-induced critical illness: Gaps in current knowledge and future translational research directions - eBioMedicine The hypothalamus-pituitary-adrenal axis in sepsis- and hyperinflammation-induced critical illness: Gaps in current knowledge and future translational research directions - eBioMedicine](https://www.thelancet.com/cms/asset/cdafec70-6b98-4f2f-809a-da4033ba30ec/gr1.jpg)